Table 1.
AML patient information
| Parameter | Characteristic | Value | |
|---|---|---|---|
| General Information | Number of patients | 45 | |
| Mean (range) age in years | 48.7 (19–65) | ||
| Mean (± SD) white blood cell count (G/l) | 45.01 ± 65.95 | ||
| Mean (range) of blastic cells in the peripheral blood (%) | 56 (0–97) | ||
| Mean (range) of blastic cells in the bone marrow (%) | 65 (20–97) | ||
| Mean (± SD) lactate dehydrogenase (U/L) | 504.4 ± 344.4 | ||
| AML subtypes based on WHO classification (n,(%)) | AML with recurrent genetic abnormalities | t(8;21)(q22;q22);(AML1/ETO) | 1 (2.2%) |
| inv [16](p13;q22) or t(16;16)(p13;q22);(CBFβ/MYH11) | 4 (8.9%) | ||
| t(9;11); MLLT3-MLL | 2 (4.4%) | ||
| AML with multilineage dysplasia without antecedent MDS | 3 (6.7%) | ||
| AML (therapy-related) | 0 (0%) | ||
| AML (not otherwise categorized; n = 35) | AML (minimally differentiated) | 4 (8.9%) | |
| AML (without maturation) | 8 (17.8%) | ||
| AML (with maturation) | 13 (28.9%) | ||
| Acute myelomonocytic leukemia (AMMoL) | 8 (17.8%) | ||
| AMMoL with eosinophilia | 0 (0.0%) | ||
| Acute monocytic leukemia | 2 (4.4%) | ||
| Acute erythroid leukemia | 0 (0.0%) | ||
| Acute megakaryoblastic leukemia | 0 (0.0%) | ||
| Mutations | FLT3-ITD/NPM1mut/CEBPAmut | 9/3/1 | |
| Induction therapy outcome | Complete remission after 1st induction | 24 | |
| Complete remission after 2nd induction | 6 | ||
| Complete remission after 3rd induction | 3 | ||
| Mortality (1st/2nd/3rd induction/consolidation) | 5/4/3/0 | ||
| Post-consolidation treatment | Allogenic hematopoietic stem cell transplant | 30 | |
| Maintenance | 3 | ||
| Risk | Favorable risk | 7 (15.6%) | |
| Intermediate risk I | 10 (22.2%) | ||
| Intermediate risk II | 8 (17.8%) | ||
| Unfavorable risk | 20 (44.4%) | ||
NPM1mut mutated nucleophosmin, CEBPAmut CCAAT/enhancer-binding protein alpha, FLT3-ITD internal tandem duplication of FMS-like tyrosine kinase 3